Sionna Therapeutics (NASDAQ:SION) Trading Up 7.7% – Here’s Why

Sionna Therapeutics, Inc. (NASDAQ:SION)’s stock price shot up 7.7% on Wednesday . The stock traded as high as $40.13 and last traded at $40.10. 36,634 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 221,865 shares. The stock had previously closed at $37.22.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SION. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. BTIG Research lifted their price objective on Sionna Therapeutics from $50.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Lifesci Capital assumed coverage on Sionna Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Stock Performance

The firm has a market capitalization of $1.77 billion and a PE ratio of -8.13. The stock’s 50 day simple moving average is $40.32 and its two-hundred day simple moving average is $29.61.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82. Following the transaction, the director directly owned 3,610,376 shares of the company’s stock, valued at $160,806,147.04. The trade was a 2.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter A. Thompson sold 94,583 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82. Following the completion of the sale, the director directly owned 3,610,376 shares of the company’s stock, valued at approximately $160,806,147.04. This trade represents a 2.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 1,522,064 shares of company stock worth $56,869,839. Corporate insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Siren L.L.C. purchased a new position in shares of Sionna Therapeutics during the 1st quarter worth $3,400,000. Zimmer Partners LP purchased a new position in Sionna Therapeutics during the first quarter worth about $2,484,000. Goldman Sachs Group Inc. acquired a new stake in shares of Sionna Therapeutics during the first quarter valued at about $667,000. Braidwell LP purchased a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at approximately $18,770,000. Finally, Prudential Financial Inc. raised its stake in shares of Sionna Therapeutics by 114.6% in the 2nd quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock valued at $2,345,000 after acquiring an additional 72,185 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.